202 related articles for article (PubMed ID: 31679211)
1. Newer Trends in Pancreatic Cancer Treatment: Genetic Alterations and the Role of Immune Therapeutic and Targeted Therapies.
Hussain I; Rashid MU; Sarvepalli D; Rahman AU; Ullah W; Badar H; Jehanzeb S; Khan AK; Khan MT; Muzammil M; Ahmad S
Crit Rev Oncog; 2019; 24(2):157-177. PubMed ID: 31679211
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
3. New targeted therapies in pancreatic cancer.
Seicean A; Petrusel L; Seicean R
World J Gastroenterol; 2015 May; 21(20):6127-45. PubMed ID: 26034349
[TBL] [Abstract][Full Text] [Related]
4. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.
Frank TS; Sun X; Zhang Y; Yang J; Fisher WE; Gingras MC; Li M
Cancer Lett; 2015 Jul; 363(1):1-6. PubMed ID: 25890222
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic developments in pancreatic cancer: current and future perspectives.
Neoptolemos JP; Kleeff J; Michl P; Costello E; Greenhalf W; Palmer DH
Nat Rev Gastroenterol Hepatol; 2018 Jun; 15(6):333-348. PubMed ID: 29717230
[TBL] [Abstract][Full Text] [Related]
6. A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution's experience.
Lowder CY; Dhir T; Goetz AB; Thomsett HL; Bender J; Tatarian T; Madhavan S; Petricoin EF; Blais E; Lavu H; Winter JM; Posey J; Brody JR; Pishvaian MJ; Yeo CJ
Surg Oncol; 2020 Jun; 33():118-125. PubMed ID: 32561076
[TBL] [Abstract][Full Text] [Related]
7. Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions.
Zhang Y; Yang C; Cheng H; Fan Z; Huang Q; Lu Y; Fan K; Luo G; Jin K; Wang Z; Liu C; Yu X
J Hematol Oncol; 2018 Jan; 11(1):14. PubMed ID: 29386069
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic Cancer Stem Cells and Therapeutic Approaches.
Ercan G; Karlitepe A; Ozpolat B
Anticancer Res; 2017 Jun; 37(6):2761-2775. PubMed ID: 28551612
[TBL] [Abstract][Full Text] [Related]
9. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
10. Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies.
Matsuoka T; Yashiro M
World J Gastroenterol; 2016 Jan; 22(2):776-89. PubMed ID: 26811624
[TBL] [Abstract][Full Text] [Related]
11. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic ductal adenocarcinoma harboring microsatellite instability / DNA mismatch repair deficiency. Towards personalized medicine.
Lupinacci RM; Bachet JB; André T; Duval A; Svrcek M
Surg Oncol; 2019 Mar; 28():121-127. PubMed ID: 30851885
[TBL] [Abstract][Full Text] [Related]
13. Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine.
Knudsen ES; O'Reilly EM; Brody JR; Witkiewicz AK
Gastroenterology; 2016 Jan; 150(1):48-63. PubMed ID: 26385075
[TBL] [Abstract][Full Text] [Related]
14. Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma.
Zhen DB; Coveler A; Zanon S; Reni M; Chiorean EG
Semin Oncol; 2018 Jun; 45(3):107-115. PubMed ID: 30391013
[TBL] [Abstract][Full Text] [Related]
15. Changing the course of pancreatic cancer--Focus on recent translational advances.
Javle M; Golan T; Maitra A
Cancer Treat Rev; 2016 Mar; 44():17-25. PubMed ID: 26924195
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma.
Zemanek T; Melichar B; Lovecek M; Soucek P; Mohelnikova-Duchonova B
Pharmacogenomics; 2019 Jan; 20(2):113-127. PubMed ID: 30539680
[TBL] [Abstract][Full Text] [Related]
17. Targeted Therapies for Pancreatic Cancer and Hurdles Ahead.
Aslan M; Shahbazi R; Ulubayram K; Ozpolat B
Anticancer Res; 2018 Dec; 38(12):6591-6606. PubMed ID: 30504367
[TBL] [Abstract][Full Text] [Related]
18. DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development.
Golan T; Javle M
J Natl Compr Canc Netw; 2017 Aug; 15(8):1063-1069. PubMed ID: 28784866
[TBL] [Abstract][Full Text] [Related]
19. Toward the goal of personalized therapy in pancreatic cancer by targeting the molecular phenotype.
Yee NS
Adv Exp Med Biol; 2013; 779():91-143. PubMed ID: 23288637
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic cancer - the past, the present, and the future.
Andersson R; Haglund C; Seppänen H; Ansari D
Scand J Gastroenterol; 2022 Oct; 57(10):1169-1177. PubMed ID: 35477331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]